Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
02/20/20187:05AMGLOBENCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer
SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for prostate cancer treatment to broadly include biomarker testing in prostate cancer. The changes to the guidelines include new... More...>>
02/15/201811:15AMGLOBEJAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Ear...
SALT LAKE CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.  A key finding is that Myriad’s EndoPredict® (EPClin... More...>>
02/07/20187:05AMGLOBEMyriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic ...
SALT LAKE CITY, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study of the Myriad myRisk® Hereditary Cancer test will be featured during the poster presentation at the 2018 Genitourinary... More...>>
02/06/20184:05PMGLOBEMyriad Genetics Reports Fiscal Second-Quarter 2018 Financial Results
Total Revenues of $194.0 Million GAAP Diluted EPS of $0.45 and Adjusted EPS of $0.31 Up 19 PercentCompany Raises Financial Guidance for Fiscal Year 2018 SALT LAKE CITY, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced... More...>>
01/25/20187:05AMGLOBEMyriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018
SALT LAKE CITY, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2018 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, February 6, 2018.  During the call, Mark C. Capone, president and CEO and Bryan... More...>>
01/22/20187:05AMGLOBEMyriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate ...
SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a new consensus statement from a team of international experts with screening recommendations on hereditary prostate cancer that... More...>>
01/12/201811:16AMGLOBEMyriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metast...
SALT LAKE CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx® for use as a companion diagnostic by healthcare professionals to identify patients... More...>>
01/03/20187:05AMGLOBEMyriad Genetics Announces Expanded Research Collaboration with AstraZeneca
SALT LAKE CITY, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from... More...>>
12/19/20177:05AMGLOBEMyriad Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual Healthcare Conference at 2:00 p.m. PT on January 8, 2018, in San Francisco... More...>>
12/12/20177:05AMGLOBEMyriad’s BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfize...
SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial showed Myriad’s BRACAnalysis CDx®  test successfully identified patients with metastatic breast cancer (MBC) who responded... More...>>
12/08/20176:00PMGLOBEMyriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict® are being featured at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.  EndoPredict... More...>>
12/06/20176:00PMGLOBEMyriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to better define the risk of breast cancer in women of European ancestry who test negative for a hereditary... More...>>
12/01/20177:40AMGLOBEInvestor Expectations to Drive Momentum within AutoNation, Regency Centers, Amphenol, LKQ, Myriad Genetics, and Pilgrim's Pri...
NEW YORK, Dec. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of AutoNation, Inc. (NYSE:AN), Regency Centers Corporation (NYSE:REG), Amphenol Corporation (NYSE:APH... More...>>
11/10/20177:05AMGLOBEMyriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Heal...
SALT LAKE CITY, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the Department of Veterans Affairs (VA) recently initiated a national, multi-center trial to evaluate the company's GeneSight® test to help improve health outcomes for... More...>>
11/09/20175:30PMGLOBEMyriad Genetics to Present at the 2017 Jefferies London Healthcare Conference
SALT LAKE CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the Jefferies Healthcare Conference at 8:40 a.m. GMT on November 16, 2017, at the Waldorf... More...>>
11/07/20174:05PMGLOBEMyriad Genetics Reports Fiscal First-Quarter 2018 Financial Results
Total Revenues of $190.2 Million Up 7 PercentGAAP Diluted EPS of $1.15 and Adjusted EPS of $0.26 Up 13 PercentGeneSight® Demonstrates Statistical Significance for Response and Remission in Prospective Study SALT LAKE CITY, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular... More...>>
11/06/20177:05AMGLOBEMyriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED) Study for the V...
BALTIMORE and SALT LAKE CITY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that they have signed an agreement to collaborate on a clinical utility study for the Vectra®... More...>>
11/02/20177:05AMGLOBEMyriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
SALT LAKE CITY, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced positive results from a double-blind, multi-center, randomized controlled trial assessing the impact of the GeneSight® Psychotropic test (GeneSight) on psychiatric treatment... More...>>
10/30/20177:05AMGLOBECrescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting
SALT LAKE CITY, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego, Calif.  Vectra DA has... More...>>
10/26/20177:05AMGLOBEEndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Br...
SALT LAKE CITY, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new positive results for EndoPredict®, a second-generation prognostic gene expression test for breast cancer.  The study found that EndoPredict (EPclin) was... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20180221 01:21:50